---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-077853"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T18:51:36.551723+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Equillium Q4 2022: $15.8M revenue from Ono deal, net income $2.8M; cash $71M into 2025

## Summary
- Revenue of $15.8M in Q4 2022 from Ono Pharmaceutical asset purchase agreement; no revenue in prior year period.
- Net income of $2.8M ($0.08 per share) in Q4 2022 vs net loss of $10.6M in Q4 2021.
- Full year 2022 net loss of $62.4M ($1.85 per share) vs $39.1M loss in 2021, including non-cash in-process R&D from Bioniz acquisition.
- Cash, cash equivalents and short-term investments total $71.0M as of Dec 31, 2022; expected to fund operations into 2025.
- Partnership with Ono for itolizumab: $26.4M upfront, up to $139M in milestones, and R&D funding.

## SEC filing metadata
- accession: 0001193125-23-077853
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000119312523077853/0001193125-23-077853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000119312523077853/d471634d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-077853
- JSON: https://secwatch.observer/filing/0001193125-23-077853.json
- Plain text: https://secwatch.observer/filing/0001193125-23-077853.txt

## Key facts
- Earnings Releases
  Equillium, Inc. reported the quarter ended December 31, 2022 results: revenue $15.8 million.
  - Period: the quarter ended December 31, 2022
  - Revenue: $15.8 million
  - Result: reported results
  source text: Revenue for the fourth quarter and full year of 2022 was $15.8 million and was derived from the company’s asset purchase agreement with Ono.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746466/000119312523077853/0001193125-23-077853-index.htm
- Earnings Releases
  Equillium, Inc. reported the year ended December 31, 2022 results: revenue $15.8 million.
  - Period: the year ended December 31, 2022
  - Revenue: $15.8 million
  - Result: reported results
  source text: Revenue for the fourth quarter and full year of 2022 was $15.8 million and was derived from the company’s asset purchase agreement with Ono.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746466/000119312523077853/0001193125-23-077853-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.